{"id":500558,"date":"2026-06-19T08:33:08","date_gmt":"2026-06-19T08:33:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/500558\/"},"modified":"2026-06-19T08:33:08","modified_gmt":"2026-06-19T08:33:08","slug":"why-this-red-hot-asx-healthcare-share-keeps-climbing","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/500558\/","title":{"rendered":"Why this red-hot ASX healthcare share keeps climbing"},"content":{"rendered":"\n

4DMedical Ltd (ASX: 4DX<\/a>) is once again one of the standout performers on the ASX. <\/p>\n

On Friday afternoon, the ASX healthcare share was up 11% to $4.29, defying a weak broader market that saw the S&P\/ASX 200 Index (ASX: XJO) fall around 1%. <\/p>\n

The longer-term performance is even more remarkable. Over the past 12 months, 4DMedical shares have soared approximately 1,616%, leaving the benchmark index’s 3.3% gain in the dust. <\/p>\n

So, what keeps driving this ASX healthcare stock<\/a> higher?<\/p>\n

\"Medical<\/p>\n

Image source: Getty Images<\/p>\n

No fresh news, plenty of momentum <\/p>\n

Interestingly, there doesn’t appear to be any new ASX announcement today that would fully explain the latest jump in the ASX healthcare share. <\/p>\n

Instead, investors seem to be continuing to respond to a string of major developments announced in recent weeks, as well as growing confidence in the company’s long-term commercial opportunity. <\/p>\n

4DMedical develops advanced respiratory imaging technology that enables clinicians to assess lung function in ways traditional imaging methods cannot. Its flagship products use proprietary software and artificial intelligence<\/a> to generate detailed functional images of the lungs, providing valuable insights for diagnosis and treatment.<\/p>\n

As healthcare systems increasingly embrace AI-powered diagnostic tools, investors appear to be betting that 4DMedical is well-positioned to benefit.<\/p>\n

Expanding globally <\/p>\n

One of the company’s most significant recent moves was its acquisition of Austrian AI imaging company Contextflow.<\/p>\n

The deal gives the $2.5 billion ASX healthcare share an immediate commercial foothold in Europe, access to lung cancer screening technology, and established reimbursement contracts in Germany.<\/p>\n

Management estimates that the acquisition will expand its addressable market by approximately 50%, significantly increasing the company’s growth runway. <\/p>\n

The transaction also strengthens 4DMedical’s position at the intersection of medical imaging and artificial intelligence, two sectors attracting substantial investor attention.<\/p>\n

Entering a multi-billion dollar US market <\/p>\n

Investors have also welcomed the company’s progress in the lucrative US healthcare market.<\/p>\n

Recently, the ASX healthcare share announced a major commercial agreement<\/a> with SimonMed, one of the largest outpatient medical imaging providers in the US, operating more than 170 imaging sites.<\/p>\n

The partnership represents another important step in the rollout of the company’s CT:VQ lung imaging technology and provides access to a large network of potential patients and healthcare providers. <\/p>\n

Earlier this month, the company also launched its CLEAR clinical program targeting acute pulmonary embolism.<\/p>\n

Management believes this initiative could expand the US addressable market for CT:VQ to around US$3 billion, highlighting the scale of the opportunity ahead if adoption continues to grow.<\/p>\n

What are the risks? <\/p>\n

Despite the excitement, investors should remember that 4DMedical remains a high-growth healthcare company.<\/p>\n

The valuation of the ASX 200 healthcare share has risen sharply, and expectations are now significantly higher than they were a year ago. Commercial adoption, reimbursement outcomes, and execution will all be critical to justifying the stock’s meteoric rise.<\/p>\n

To keep the momentum going, management will need to continue converting clinical success into revenue growth, expand adoption of its technology across healthcare networks, and successfully integrate its European expansion strategy.<\/p>\n

If it can deliver on those objectives, investors may believe the company’s remarkable run still has further to go.<\/p>\n","protected":false},"excerpt":{"rendered":"4DMedical Ltd (ASX: 4DX) is once again one of the standout performers on the ASX. On Friday afternoon,…\n","protected":false},"author":2,"featured_media":85673,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[163,521,85,46],"class_list":["post-500558","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-health","tag-healthcare","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/500558","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=500558"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/500558\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/85673"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=500558"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=500558"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=500558"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}